EP1077958A1 - Acides oxazol-aryl-carboxyliques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie - Google Patents

Acides oxazol-aryl-carboxyliques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie

Info

Publication number
EP1077958A1
EP1077958A1 EP99924163A EP99924163A EP1077958A1 EP 1077958 A1 EP1077958 A1 EP 1077958A1 EP 99924163 A EP99924163 A EP 99924163A EP 99924163 A EP99924163 A EP 99924163A EP 1077958 A1 EP1077958 A1 EP 1077958A1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
alkyl
hydrogen
aryl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99924163A
Other languages
German (de)
English (en)
Inventor
Michael Sotirios Malamas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of EP1077958A1 publication Critical patent/EP1077958A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • Hyperinsulinemia can be present as a result of insulin resistance, such as is in obese and/or diabetic (NIDDM) subjects and/or glucose intolerant subjects, or in IDDM subjects, as a consequence of over injection of insulin compared with normal physiological release of the hormone by the endocrine pancreas.
  • NIDDM diabetic diabetic
  • IDDM glucose intolerant subjects
  • Atherosclerosis has been well established by numerous experimental, clinical and epidemiological studies (summarized by Stout, Metabolism 1985, 34, 1, and in more detail by Pyorala et al, Diabetes/Metabolism Reviews 1987, 3, 463). Statistically significant plasma insulin elevations at 1 and 2 hours after oral glucose load correlates with an increased risk of coronary heart disease.
  • the independent risk factors obesity and hypertension for atherosclerotic diseases are also associated with insulin resistance.
  • insulin resistance is located in peripheral tissues (principally muscle) and correlates directly with the severity of hypertension (DeFronzo and Ferrannini, Diabetes Care 1991, 14, 173).
  • insulin resistance generates hyperinsulinemia, which is recruited as a mechanism to limit further weight gain via thermogenesis, but insulin also increases renal sodium reabsorption and stimulates the sympathetic nervous system in kidneys, heart, and vasculature, creating hypertension.
  • insulin resistance is usually the result of a defect in the insulin receptor signaling system, at a site post binding of insulin to the receptor.
  • Accumulated scientific evidence demonstrating insulin resistance in the major tissues which respond to insulin strongly suggests that a defect in insulin signal transduction resides at an early step in this cascade, specifically at the insulin receptor kinase activity, which appears to be diminished (reviewed by Haring, Diabetalogia 1991, 34, 848).
  • PTPases Protein-tyrosine phosphatases play an important role in the regulation of phosphorylation of proteins.
  • the interaction of insulin with its receptor leads to phosphorylation of certain tyrosine molecules within the receptor protein, thus activating the receptor kinase.
  • PTPases dephosphorylate the activated insulin receptor, attenuating the tyrosine kinase activity.
  • PTPases can also modulate post-receptor signaling by catalyzing the dephosphorylation of cellular substrates of the insulin receptor kinase.
  • the enzymes that appear most likely to closely associate with the insulin receptor and therefore, most likely to regulate the insulin receptor kinase activity include PTP1B, LAR, PTP ⁇ and SH-PTP2 (B.
  • the compounds of this invention have been shown to inhibit PTPases derived from rat liver microsomes and human-derived recombinant PTPase- IB (hPTP-lB) in vitro. They are useful in the treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels.
  • This invention provides a compound of formula I having the structure
  • R 1 is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, thienyl, furyl, pyridyl,
  • R 2 is hydrogen, alkyl of 1-6 carbon atoms, or aryl of 6 to 10 carbon atoms;
  • R 3 and R 4 are independently halogen, hydrogen, alkyl of 1-12 carbon atoms , aryl of 6 to 10 carbon atoms; halogen, trifluoromethylof 1-6 carbon atoms, alkoxyaryl of
  • R 5 is hydrogen, alkyl of 1-6 carbon atoms, -CH(R 8 )R 9 , -C(CH 2 ) n CO 2 R 10 ,
  • R 6 is hydrogen, alkyl of 1-6 carbon atoms, halogen, alkyoxy of 1-6 carbon atoms, trifluoroalkyl of 1-6 carbon atoms or trifluoroalkoxy of 1-6 carbon atoms;
  • R 7 is hydrogen or alkyl of 1 to 6 carbon atoms
  • R 8 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, arylalkyl of 7-15 carbon atoms, cycloalkyl of 3-8 carbon atoms, phthalic acid,
  • R 9 is CO 2 R 12 , CONHR 12 , tetrazole, PO 3 R 12 ;
  • R 10 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms;
  • R 1 is alkylene of 1 to 3 carbon atoms
  • R 12 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms;
  • X is O, or S
  • Y is O, N, or S
  • Z is C, or N
  • Pharmaceutically acceptable salts can be formed from organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable acids when a compound of this invention contains a basic moiety.
  • organic and inorganic acids for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulf
  • Salts may also be formed from organic and inorganic bases, preferably alkali metal salts, for example, sodium, lithium, or potassium, when a compound of this invention contains a carboxylate or phenolic moiety, or similar moiety capable of forming base addition salts.
  • alkali metal salts for example, sodium, lithium, or potassium
  • Alkyl includes both straight chain as well as branched moieties.
  • Halogen means bromine, chlorine, fluorine, and iodine.
  • the aryl portion of the aryl or aralkyl substituent is a phenyl, naphthyl or l,4-benzodioxan-5-yl group; with phenyl being most preferred.
  • the aryl moiety may be optionally mono-, di-, or tri- substituted with a substituent selected from the group consisting of alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoromethyl, halogen, alkoxycarbonyl of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms, and dialkylamino in which each of the alkyl groups is of 1-6 carbon atoms, nitro, cyano, -CO 2 H, alkylcarbonyloxy of 2-7 carbon atoms, and alkylcarbonyl of 2-7 carbon atoms.
  • the compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers. While shown without respect to stereochemistry in Formula I, the present invention includes such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof.
  • Preferred compounds of this invention are those compounds of Formula I, X is oxygen. More preferred compouds of this invention are those compounds of of Formula I, wherein: X is O;
  • R 1 is phenyl substituted with R 6 ;
  • R 2 is alkyl of 1-6 carbon atoms
  • R 3 and R 4 are each, independently, hydrogen or halogen.
  • the compounds of this invention can be prepared according to the following schemes from commercially available starting materials or starting materials which can be prepared using to literature procedures. These Schemes show the preparation of representative compounds of this invention.
  • Oxazoles (3) were coupled with aryl boronic acids of general structure (4; R 3 , R 4 are alkyl, aryl, trifluoromethyl, substituted aryl, nitro, carbocyclic 5 to 7 carbon atoms rings or heterocyclic rings 5 to 7 atom rings with from 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur) using the Suzuki protocol [ref. Syn. Comm. 1981, 11, 513-519] to produce biphenyls (5).
  • the aryl boronic acids are either commercially available or can be prepared according to known methodology [ref. J. Org. Chem, 1984, 49, 5237-5243].
  • Biphenyls (5) converted to phenols (6) by treatment with boron tribromide in dichloromethane [ref. J. Org. Chem. 1974, 39, 1427-1429].
  • Phenols (6) were alkylated with bromo or chloro-alkylcarboxylates [(Br or Cl)(CH 2 ) n CO 2 R 12 ] in the presence of sodium hydride or potassium carbonate, using dimethylformamide or acetonitrile as the solvent. Subsequent saponification with sodium hydroxide in methyl alcohol and tetrahydrofuran produced biphenyls (7).
  • thiazoles (10) were brominated with bromine in the presence of sodium acetate.
  • the 4-bromo-thiazoles (11) were coupled with 4, 4'-methoxy biphenyl boronic acid using the Suzuki protocol [ref. Syn. Comm. 1981, 11, 513-519] to give biphenyls (12).
  • Biphenyls (12) were further converted to the desired products in substantially the same manner as described in Scheme I.
  • the biphenyl compounds (13 ) can be monobrominated or dibrominated using bromine, potassium acetate and acetic acid.
  • the Suzuki coupling protocol [ref. Syn. Comm. 1981, 11, 513-519] was used to generate the terphenyls 15 and 16.
  • heterocyclic boronic acids for example thiophene, furan, oxazole, thiazole, pyridine.
  • oxazoles (3) were coupled with aryl boronic acids of general structure (4; R 3 , R 4 are alkyl, aryl, trifluoromethyl, substituted aryl, nitro, carbocyclic 5 to 7 carbon atoms rings or heterocyclic rings 5 to 7 atom rings with from 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur) using the Suzuki protocol [ref. Syn. Comm. 1981, 11, 513-519] to produce biphenyls (17).
  • Biphenyls (17) were converted to oximes (18) with hydroxylamine in the presence of sodium acetate.
  • Oximes (18) were reduced with sodium cyanoborohydride under acidic conditions to produce to hydroxylamines (19).
  • hydroxylamines (19) were treated with N- (chlorocarbonyl)isocyanate to produce oxadiazolidinediones (20).
  • Thiazolidinediones were prepared from benzaldehydes (17) using known methodology [ref. J. Med. Chem., 1992, 35, 1853-1864].
  • the compounds of this invention are useful in treating metabolic disorders related to insulin resistance or hyperglycemia, typically associated with obesity or glucose intolerance.
  • the compounds of this invention are therefore, particularly useful in the treatment or inhibition of type II diabetes.
  • the compounds of this invention are also useful in modulating glucose levels in disorders such as type I diabetes.
  • This standard pharmacological test procedure assess the inhibition of rat hepatic microsomal PTPase activity using, as substrate, the phosphotyrosyl dodecapeptide corresponding to the 1142-1153 insulin receptor kinase domain, phosphorylated on the
  • Rats (Male Sprague-Dawley rats (Charles River, Springfield, NY) weighing 100-150 g, maintained on standard rodent chow (Purina)) are sacrificed by asphyxiation with CO2 and bilateral thoracotomy. The liver is removed and washed in cold 0.85% (w/v) saline and weighed. The tissue is homogenized on ice in 10 volumes of Buffer A and the microsomes are isolated essentially as described by Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus.
  • liver homogenate is filtered through silk to remove any remaining tissue debris and then is centrifuged at 10,000xg for 20 minutes at 40C. The supernatant is decanted and centrifuged at 100,000xgfor 60 minutes at 40C.
  • the pellet, microsomes and small vesicles is resuspended and lightly homogenized in : 20 mM TRIS-HC1 (pH 7.4), 50 mM 2-mercaptoethanol, 250 mM sucrose, 2 mM EDTA, 10 mM EGTA, 2 mM AEBSF, 0.1 mM TLCK, 0.1 mM TPCK, 0.5 mM benzamidine, 25 ug/ml leupeptin, 5 ug/ml pepstatin A, 5 ug/ml;H5B antipain, 5 ug/ml chymostatin, 10 ug/ml aprotinin (Buffer A), to a final concentration of approximately 850 ug protein/ml. Protein concentration is determined by the Pierce Coomassie Plus Protein Assay using crystalline bovine serum albumin as a standard (Pierce Chemical Co., Rockford, IL).
  • the microsomal fraction (83.25 ul) is preincubated for 10 min at 37deg.C with or without test compound (6.25ul) and 305.5 ul of the 81.83 mM HEPES reaction buffer, pH 7.4.
  • Peptide substrate, 10.5 ul at a final concentration of 50 uM, is equilibrated to 37deg.C in a LABLINE Multi-Blok heater equipped with a titerplate adapter.
  • the preincubated microsomal preparation (39.5 ul) with or without drug is added to initiate the dephosphorylation reaction, which proceeds at 37deg.C for 30 min.
  • the reaction is terminated by the addition of 200 ul of the malachite green- ammonium molybdate-Tween 20 stopping reagent (MG/AM/Tw).
  • the stopping reagent consists of 3 parts 0.45% malachite green hydrochloride, 1 part 4.2% ammonium molybdate tetrahydrate in 4 N HCI and 0.5% Tween 20.
  • Sample blanks are prepared by the addition of 200 ul MG/AM/Tw to substrate and followed by 39.5 ul of the preincubated membrane with or without drug.
  • sample absorbances are determined at 650 nm using a platereader (Molecular Devices). Samples and blanks are prepared in quadruplicates. Screening activity of 50 uM (final) drug is accessed for inhibition of microsomal PTPases.
  • PTPase activities based on a potassium phosphate standard curve, are expressed as nmoles of phosphate released/min/mg protein. Test compound PTPase inhibition is calculated as percent of control. A four parameter non-linear logistic regression of PTPase activities using SAS release 6.08, PROC NLIN, is used for determining IC50 values of test compounds. All compounds were administered at a concentration of 50 uM. The following results were obtained using representative compounds of this invention.
  • This standard pharmacological test procedure assess the inhibition of recombinant rat protein tyrosine phosphatase, PTP1B, activity using, as substrate, the phosphotyrosyl dodecapeptide corresponding to the 1142-1153 insulin receptor kinase domain, phosphorylated on the 1146, 1150 and 1151 tyrosine residues.
  • the procedure used and results obtained are briefly described below.
  • Human recombinant PTP1B was prepared as described by Goldstein (see Goldstein et al. Mol. Cell. Biochem. 109, 107, 1992).
  • the enzyme preparation used was in microtubes containing 500-700 ⁇ g/ml protein in 33 mM Tris-HCl, 2 mM EDTA, 10% glycerol and 10 mM 2-mercaptoethanol.
  • the malachite green-ammonium molybdate method as described (Lanzetta et al. Anal. Biochem. 100, 95, 1979) and adapted for a platereader, is used for the nanomolar detection of liberated phosphate by recombinant PTP1B.
  • the test procedure uses, as substrate, a dodecaphosphopeptide custom synthesized by AnaSpec, Inc. (San Jose, CA).
  • the peptide, TRDIYETDYYRK corresponding to the 1142-1153 catalytic domain of the insulin receptor, is tyrosine phosphorylated on the 1146, 1150, and 1151 tyrosine residues.
  • the recombinant rPTPlB is diluted with buffer (pH 7.4, containing 33 mM Tris-HCl, 2 mM EDTA and 50 mM b-mercaptoethanol) to obtain an approximate activity of 1000- 2000 nmoles/min/mg protein.
  • the diluted enzyme (83.25 mL) is preincubated for 10 min at 37°C with or without test compound (6.25 mL) and 305.5 mL of the 81.83 mM HEPES reaction buffer, pH 7.4 peptide substrate, 10.5 ml at a final concentration of 50 mM, and is equilibrated to 37°C. in a LABLINE Multi-Blok heater equipped with a titerplate adapter.
  • the preincubated recombinant enzyme preparation (39.5 ml) with or without drug is added to initiate the dephosphorylation reaction, which proceeds at
  • the reaction is terminated by the addition of 200 mL of the malachite green-ammonium molybdate-Tween 20 stopping reagent (MG/AM/Tw).
  • the stopping reagent consists of 3 parts 0.45% malachite green hydrochloride, 1 part 4.2% ammonium molybdate tetrahydrate in 4 N HCI and 0.5% Tween 20.
  • Sample blanks are prepared by the addition of 200 mL MG/AM/Tw to substrate and followed by 39.5 ml of the preincubated recombinant enzyme with or without drug. The color is allowed to develop at room temperature for 30 min. and the sample absorbances are determined at 650 nm using a platereader (Molecular Devices). Sample and blanks are prepared in quadruplicates.
  • PTPase activities based on a potassium phosphate standard curve, are expressed as nmoles of phosphate released/min/mg protein. Inhibition of recombinant PTP1B by test compounds is calculated as percent of phosphatase control.
  • the non-insulin dependent diabetic (NIDDM) syndrome can be typically characterizes by obesity, hyperglycemia, abnormal insulin secretion, hyperinsulinemia and insulin resistance.
  • the genetically obese-hyperglycemic ob/ob mouse exhibits many of these metabolic abnormalities and is thought to be a useful model to search for hypoglycemic agents to treat NIDDM [Coleman, D.: Diabetologia 14: 141-148, 1978].
  • mice [Male or female ob/ob (C57 B1/6J) and their lean litermates (ob/+ or +/+, Jackson Laboratories) ages 2 to 5 months (10 to 65 g)] of a similar age were randomized according to body weight into 4 groups of 10 mice. The mice were housed 5 per cage and are maintained on normal rodent chow with water ad libitum. Mice received test compound daily by gavage (suspended in 0.5 ml of 0.5% methyl cellulose); dissolved in the drinking water; or admixed in the diet. The dose of compounds given ranges from 2.5 to 200 mg/kg body weight/day. The dose is calculated based on the fed weekly body weight and is expressed as active moiety.
  • mice received vehicle only.
  • Statistically (p ⁇ 0.05) significant Based on the results obtained in the standard pharmacological test procedures, representative compounds of this invention have been shown to inhibit PTPase activity and lower blood glucose levels in diabetic mice, and are therefore useful in treating metabolic disorders related to insulin resistance or hyperglycemia, typically associated with obesity or glucose intolerance. More particularly, the compounds of this invention useful in the treatment or inhibition of type II diabetes, and in modulating glucose levels in disorders such as type I diabetes. As used herein, the term modulating means maintaining glucose levels within clinically normal ranges.
  • Effective administration of these compounds may be given at a daily dosage of from about 1 mg kg to about 250 mg/kg, and may given in a single dose or in two or more divided doses. Such doses may be administered in any manner useful in directing the active compounds herein to the recipient's bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal and subcutaneous injections), rectally, vaginally, and transdermally.
  • transdermal administrations are understood to include all administrations across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues.
  • Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).
  • Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions.
  • Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc.
  • Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethyl- cellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar.
  • pharmaceutically acceptable diluents including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, micro
  • Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compound(s).
  • Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin.
  • Water soluble suppository bases such as polyethylene glycols of various molecular weights, may also be used.
  • the dosage, regimen and mode of administration of these compounds will vary according to the malady and the individual being treated and will be subject to the judgment of the medical practitioner involved. It is preferred that the administration of one or more of the compounds herein begin at a low dose and be increased until the desired effects are achieved.
  • Step b) 4-(4-Bromo-phenyl)-5-methyl-2-(4-trifluoromethyl-phenyl)-oxazole
  • Step c) 4-(4 , -methoxy-biphenyl-4-ylV5-methyl-2-(4-trifluoromethyl-phenyl)-oxazole 4-Methoxy-benzeneboronic acid (1.44 g, 7.19 mmol) in ethyl alcohol (5 mL) was added into a mixture of 4-(4-bromo-phenyl)-5-methyl-2-(4-trifluoromethyl- phenyl)-oxazole (2.5 g, 6.54mmol), sodium carbonate (2N, 6.5 mL), tetrakis- (triphenylphosphine)palladium(O) (0.23 g, 0.196 mmol), and toluene (200 mL).
  • the title compound was prepared from 4-(4-bromo-phenyl)-5-methyl-2-(4- trifluoromethyl-phenyl)-oxazole, and 4-methoxy-benzeneboronic acid in substantially the same manner, as described in Example 1 step c, and was obtained as a white solid, mp 93-94 °C; MS m/e 409 (M + );
  • the title compound was prepared from 4-(4'-methoxy-biphenyl-3-yl)-5-methyl- 2-(4-trifluoromethyl-phenyl)-oxazole, in substantially the same manner, as described in Example 3, and was obtained as a white solid, mp 133-135 °C; MS m/e 395 (M + );
  • reaction mixture was stirred for 30 minutes, poured into water, acidified with HCI
  • Example 7 and was obtained as a white solid, mp 148-149 °C; MS m/e 543 (M + ); Analysis for: C 32 H 24 F 3 NO 4 Calc'd: C, 70.71; H, 4.45; N, 2.58 Found: C, 70.72; H ,
  • This compound was prepared from 4-(4-bromo-phenyl)-5-methyl-2-(4- trifluoromethyl-phenyl)-oxazole, and 4-formylbenzeneboronic acid in substantially the same manner, as described in Example 1 step c, and was obtained as an off-white solid;
  • This compound was prepared from 4'-[5-methyl-2-(4-trifluoromethyl-phenyl)- oxazol-4-yl]-biphenyl-4-carbaldehyde, and hydroxylamine in substantially the same manner, as described in Example 1 step a, and was obtained as an off-white solid; MS m/e 422 (M + );
  • N-(Chlorocarbonyl)isocyanate (0.2 mL, 2.6 mmol) was added dropwise into a cold (-5 °Q mixture of N- ⁇ 4'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]- biphenyl-4-ylmethyl ⁇ -hydroxylamine (1.1, 2.6 mmol), and tetrahydrofuran (20.0 mL).
  • reaction mixture was stirred for 30 minutes, poured into water, acidified with HCI
  • This compound was prepared from 3-(4-bromo-phenyl)-5-methyl-2-(4- trifluoromethyl-phenyl)-oxazole in substantially the same manner, as described in
  • Example 1 steps a-d, and was obtained as a white solid, mp 216-218; MS m/e 493 (M + );
  • This compound was prepared from l-(6-methoxy-naphthalen-2-yl)propanone oxime, and 4-trifluoromethyl-phenyl acetyl chloride in substantially the same manner, as described in Example 1 steps b, and was obtained as a white solid, mp 138-139; MS m/e 383 (M + ); Analysis for: C 22 H 19 F 3 NO 2 Calc'd: C, 68.93; H, 4.21; N, 3.65 Found: C, 68.83; H,
  • This compound was prepared from 4'-(6-methoxy-naphthalen-2-yl)-5-methyl- 2-(4-trifluoromethyl-phenyl)-oxazole and boron tribromide in substantially the same manner, as described in Example 3, and was obtained as a white solid, mp 188-191; MS m/e 370 (M+H) + ;
  • This compound was prepared from 4'-(6-hydroxy-naphthalen-2-yl)-5-methyl-2- (4-trifluoromethyl-phenyl)-oxazole and bromine in substantially the same manner, as described in Example 9, and was obtained as an off-white solid; MS m/e 447 (M + ); Analysis for: C 21 H 13 BrF 3 NO 2 Calc'd: C, 56.27; H, 2.92; N, 3.12 Found: C, 56.20; H, 2.66; N, 3.15
  • This compound was prepared from 4'-(5-bromo-6-hydroxy-naphthalen-2-yl)-5- methyl-2-(4-trifluoromethyl-phenyl)-oxazole and methyl bromoacetate in substantially the same manner, as described in Example 5, and was obtained as white solid, mp 212- 214 °C; MS m/e 506 (M+H) + ; Analysis for: C 23 H 15 BrF 3 NO 4 Calc'd: C, 54.57; H, 2.99; N, 2.77 Found: C, 54.17; H, 2.69; N, 2.76
  • This compound was prepared from 4'-(5-bromo-6-hydroxy-naphthalen-2-yl)-5- methyl-2-(4-trifluoromethyl-phenyl)-oxazole and methyl bromoacetate in substantially the same manner, as described in Example 7, and was obtained as an off-white solid, mp 195-197 °C; MS m/e 596 (M+H) + ; Analysis for: C 30 H 21 BrF 3 NO 4 Calc'd: C, 60.42; H, 3.55; N, 2.35 Found: C, 60.31; H,

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'invention concerne des composés de la formule structurelle (I) dans laquelle R représente un groupe (a) ou un groupe (b), A représente OR5 ou un groupe (c), R1 représente alkyle C¿1-6?, cycloalkyle C3-8, thiényle, furyle, pyridyle, un groupe (d) ou (e), R?2¿ représente hydrogène, alkyle C¿1-6?, ou aryle C1-6, R?3 et R4¿ représentent indépendamment halogène, hydrogène, alkyle C¿1-12?, aryle C6-10, halogène, trifluorométhyle C1-6, alcoxyaryle C7-14, nitro, amino, carboalcoxy, carbamide, carbamate, urée, alkylsulfoamide, -NR?7(CH¿2)mCO2H, arylsulfoamide, cycloalkyle C3-8, ou hétérocycle contenant 5 à 7 chaînons contenant de 1 à 3 hétéroatomes choisis parmi oxygène, azote, ou soufre, R5 représente hydrogène, alkyle C¿1-6?, -CH(R?8)R9¿, -C(CH¿2?)nCO2R?10¿, -C(CH¿3?)2CO2R?10, -CH(R8)(CH¿2)nCO2R?10, -CH(R8)C¿6H4CO2R10, ou CH¿2?-tétrazole, R?6¿ représente hydrogène, alkyle C¿1-6?, halogène, alkyoxy C1-6, trifluoroalkyle C1-6, ou trifluoroalcoxy C1-6. L'invention concerne également un sel de ces composés, acceptable sur le plan pharmacologique. Ces composés et ce sel sont utiles dans le traitement de troubles métaboliques associés à l'insulinorésistance ou à l'hyperglycémie.
EP99924163A 1998-05-12 1999-05-10 Acides oxazol-aryl-carboxyliques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie Withdrawn EP1077958A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7671098A 1998-05-12 1998-05-12
US76710 1998-05-12
PCT/US1999/010183 WO1999058511A1 (fr) 1998-05-12 1999-05-10 Acides oxazol-aryl-carboxyliques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie

Publications (1)

Publication Number Publication Date
EP1077958A1 true EP1077958A1 (fr) 2001-02-28

Family

ID=22133734

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99924163A Withdrawn EP1077958A1 (fr) 1998-05-12 1999-05-10 Acides oxazol-aryl-carboxyliques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie

Country Status (6)

Country Link
EP (1) EP1077958A1 (fr)
JP (1) JP2002514631A (fr)
CN (1) CN1308618A (fr)
AU (1) AU4073299A (fr)
CA (1) CA2331118A1 (fr)
WO (1) WO1999058511A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432706A2 (fr) * 2001-09-26 2004-06-30 Bayer Pharmaceuticals Corporation Thiazoles 3-pyridyle ou 4-isoquinolinyle utilises comme inhibiteurs de lyase c17,20
AU2002349705A1 (en) 2001-12-03 2003-06-17 Japan Tobacco Inc. Azole compound and medicinal use thereof
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
AU2005236055B2 (en) 2004-04-20 2011-10-06 Transtech Pharma, Llc Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
WO2006023865A1 (fr) 2004-08-23 2006-03-02 Wyeth Acides d'oxazolo-naphthyl utilises en tant modulateurs de l'inhibiteur de type-1 (pai-1) de l'activateur de plasminogene utiles dans le traitement de la thrombose et des maladies cardio-vasculaires
AU2005277137A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
CN101044127A (zh) 2004-08-23 2007-09-26 惠氏公司 用作纤溶酶原激活剂抑制剂－1的噻唑基－萘基酸
US8563742B2 (en) 2008-08-29 2013-10-22 High Point Pharmaceuticals, Llc Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
CN106749169B (zh) * 2016-11-07 2020-04-21 浙江工业大学 一种Ertiprotafib的手性制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58183676A (ja) * 1982-04-19 1983-10-26 Takeda Chem Ind Ltd オキサゾ−ル誘導体
CA2009470A1 (fr) * 1989-02-08 1990-08-08 Yu Momose Composes d'oxazole et leur utilisation
US5591862A (en) * 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9958511A1 *

Also Published As

Publication number Publication date
CN1308618A (zh) 2001-08-15
CA2331118A1 (fr) 1999-11-18
WO1999058511A1 (fr) 1999-11-18
AU4073299A (en) 1999-11-29
JP2002514631A (ja) 2002-05-21

Similar Documents

Publication Publication Date Title
US6166069A (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6110963A (en) Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
WO1999058519A1 (fr) Acides phenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
US6232322B1 (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
EP1077967B1 (fr) Acides biphenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
US6699896B1 (en) Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
AU756337B2 (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
JP2002514638A (ja) インスリン抵抗性および高血糖症の治療に有用な１１−アリール−ベンゾ［ｂ］ナフト［２，３−ｄ］フラン類および１１−アリール−ベンゾ［ｂ］ナフト［２，３−ｄ］チオフェン類
US6310081B1 (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
EP1077958A1 (fr) Acides oxazol-aryl-carboxyliques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
US6221902B1 (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6057316A (en) 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
US6001867A (en) 1-aryl-dibenzothiophenes
EP1077966B1 (fr) Acides biphenyl-sulfonyl-aryl-carboxyliques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
US6340676B2 (en) 4-aryl-1-oxa-9-thia-cyclopenta (b) fluorenes
MXPA00011090A (en) Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
MXPA00011083A (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
MXPA00011085A (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
MXPA00011086A (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001019;LT PAYMENT 20001019;LV PAYMENT 20001019;RO PAYMENT 20001019;SI PAYMENT 20001019

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH

17Q First examination report despatched

Effective date: 20030327

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030807